Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03310983 · ClinicalTrials.gov registry record
Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation
A clinical trial, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- 254
- Enrollment target
NCT03310983: Completed study, sponsored by University of Kansas Medical Center.
NCT03310983 is a clinical trial that has completed, run by University of Kansas Medical Center. The registered enrollment target is 254 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03310983 has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- 254 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if participants in the ADORE study (NCT02626299), who took a DHA supplement during pregnancy, see favorable body fat in their infants from birth to 24 months, and if excessive or appropriate weight gain during pregnancy impacts this result.
Primary Outcome
Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2022-08-31 |
What the finished NCT03310983 record still lists
NCT03310983 is an observational study that tracks outcomes without assigning an intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03310983 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03310983 about?
NCT03310983 is a clinical study titled "Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation". The purpose of this study is to learn if participants in the ADORE study (NCT02626299), who took a DHA supplement during pregnancy, see favorable body fat in their infants from birth to 24 months, and if excessive or appropriate weight gain during pregnancy impacts this result.
What is the current status of trial NCT03310983?
This trial is currently completed. The enrollment target is 254 participants. The study started on 2017-11-01. Estimated completion is 2022-08-31.
Who is sponsoring clinical trial NCT03310983?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI